🔎 Trials Near Me

Beranda › Leukemia Mieloid Fase Kronis › New York

Uji klinis Leukemia Mieloid Fase Kronis di New York

5 studi untuk Leukemia Mieloid Fase Kronis mencari peserta di lokasi di New York.

Kota di New York

Teks studi resmi (Bahasa Inggris)

Study of Olverembatinib (HQP1351) in Patients With CML-CP

  • Ascentage Investigative Site #1068, Rochester
  • Ascentage Investigative Site #1053, Shirley
  • Ascentage Investigative Site #1160, Stony Brook
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06423911

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • Memorial Sloan Kettering Cancer Center, New York
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04838041

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

  • NY Cancer and Blood Specialists, East Setauket
  • SUNY Upstate Medical University, Syracuse
Menerima pesertaStudi observasional
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT07091019

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

  • Memorial Sloan Kettering Cancer Center, New York
  • Montefiore Medical Center, The Bronx
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Apr 2026 · NCT05304377

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

  • Memorial Sloan Kettering Cancer Center - Main Campus, New York
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jan 2026 · NCT06163430

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.